This is the Magellan website for behavioral health providers
Magellan Health

Medication-Assisted Treatment (MAT) 

Our national MAT initiative seeks to increase the use of acamprosate, naltrexone (both in oral and injectable form), buprenorphine and new medications as their proven benefits emerge — in combination with proven psychosocial interventions — in the treatment of substance use disorders where clinically appropriate. 

How does Magellan’s program work?

  • Focuses on patients who have been discharged from inpatient substance use treatment programs
  • Targets individuals receiving outpatient case or disease management services
  • Monitors the number of cases in which physicians are prescribing medications and follows member readmission rates
  • Involves continual collaboration with Magellan’s health plan partners to help facilitate the incorporation of these medications into client formularies
  • Advocates provider education on the importance of using appropriate medications when developing members’ substance use disorder treatment plans.